» Articles » PMID: 38371170

Pulmonary Tumor Thrombotic Microangiopathy in a Patient with Rapid Progressive Triple-Negative Breast Cancer

Overview
Journal Case Rep Oncol
Publisher Karger
Specialty Oncology
Date 2024 Feb 19
PMID 38371170
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Pulmonary tumor thrombotic microangiopathy (PTTM) is a rare complication of metastatic carcinoma, which occurs in patients with pulmonary arterial hypertension, and is mostly fatal. Circulating tumor cell clusters have been recognized as critical factors during breast cancer progression.

Case Presentation: An 80-year-old woman with triple-negative breast cancer was admitted to our hospital with progressive dyspnea and lower back pain. Breast cancer treatment included mastectomy, neoadjuvant and adjuvant chemotherapy as well as adjuvant radiotherapy, receiving her last cycle of radiotherapy 8 days before death. At admission, D-dimers were strongly elevated and platelets were low. NT-pro-BNP was moderately elevated. A CT scan of the chest did not show pulmonary embolism but revealed interlobular septal thickening, centrilobular consolidation, and distension of the pulmonary arteries. Moreover, new skeletal and most likely lymphatic metastasis was described. Treatment with oxygen and oral glucocorticoids was initiated, assuming radiotherapy-induced pneumonitis. Due to low expression of PD-L1 and her markedly bad performance status, tumor-specific therapy was not possible, and the treatment regimen was changed to best supportive care. The patient died 8 days after admission. Autopsy revealed numerous events consistent with tumor emboli in the pulmonary vessels, suggesting PTTM.

Conclusion: PTTM is a rare and mostly fatal complication in malignant breast cancer. As an early detection is difficult, further investigation is needed. Circulating tumor cluster cells may be one way to detect PTTM early and improve patients' survival.

Citing Articles

Cancer as an Individual Risk Factor for Heart Failure: A Review of Literature.

Rivera Boadla M, Sharma N, Khan M, Khurana S, Gulati A, Tan S Cureus. 2024; 16(5):e60592.

PMID: 38894762 PMC: 11185020. DOI: 10.7759/cureus.60592.

References
1.
Godbole R, Saggar R, Kamangar N . Pulmonary tumor thrombotic microangiopathy: a systematic review. Pulm Circ. 2019; 9(2):2045894019851000. PMC: 6540517. DOI: 10.1177/2045894019851000. View

2.
Neverauskaite-Piliponiene G, Cesas K, Pranys D, Miliauskas S, Padervinskiene L, Laukaitiene J . Fatal pulmonary tumour thrombotic microangiopathy in patient with ovarian adenocarcinoma: review and a case report. BMC Cardiovasc Disord. 2022; 22(1):1. PMC: 8729036. DOI: 10.1186/s12872-021-02434-3. View

3.
Siegel R, Miller K, Fuchs H, Jemal A . Cancer statistics, 2022. CA Cancer J Clin. 2022; 72(1):7-33. DOI: 10.3322/caac.21708. View

4.
Yoshikawa S, Hara T, Suzuki M, Fujioka M, Taniguchi Y, Hirata K . Imatinib Dramatically Improved Pulmonary Hypertension Caused by Pulmonary Tumor Thrombotic Microangiopathy (PTTM) Associated with Metastatic Breast Cancer. Int Heart J. 2020; 61(3):624-628. DOI: 10.1536/ihj.19-556. View

5.
Ren W, Chen M, Qiao Y, Zhao F . Response to comment on: "Global guidelines for breast cancer screening: A systematic review". Breast. 2022; 67:131. PMC: 9982310. DOI: 10.1016/j.breast.2022.08.004. View